Skip to site menu Skip to page content
Logo Image
In Brief
Spotlight

Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal

Innovent Biologics will receive $650m upfront and could earn up to $9.85bn in additional milestone payments.

Latest news

Psychedelic-assisted therapies get a boost, but systems struggle to play catch-up

As the first psychedelics near approval, several other factors warrant attention to ensure effective and safe implementation.

GSK’s Nucala secures NICE COPD endorsement

NICE now recommends Nucala for both severe asthma and COPD, expanding the drug’s clinical uptake across the UK’s public health service.

Healthcare cost inflation is back in the headlines

Rising medical costs, which are caused in part by the external trade pressure in the Gulf, are a key risk factor driving household debt and widening access inequality globally.

FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on AstraZeneca’s oral SERD for breast cancer.

FDA grants priority review for Sanofi’s venglustat NDA

The decision is anticipated by 25 November 2026.